Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
JCO Precision Oncology|May 5, 2025
Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients With Metastatic Invasive Lobular Carcinoma of the BreastJulia Foldi, Steffi Oesterreich, Antony Tin, et al.
Research Square|August 26, 2024
Immune Infiltration Correlates with Transcriptomic Subtypes in Primary ER+ Invasive Lobular Breast CancerFangyuan Chen, Sayali Onkar, Jian Zou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2022
Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBCJulia Foldi, Adriana Kahn, Andrea Silber, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 15, 2016
Cytomegalovirus Infection after CD34(+)-Selected Hematopoietic Cell TransplantationYao-Ting Huang, Dionysios Neofytos, Julia Foldi, et al.
NPJ Precision Oncology|November 9, 2024
Immune infiltration correlates with transcriptomic subtypes in primary estrogen receptor positive invasive lobular breast cancerFangyuan Chen, Sayali Onkar, Jian Zou, et al.
Nature Immunology|May 22, 2012
Notch-RBP-J signaling regulates the transcription factor IRF8 to promote inflammatory macrophage polarizationHaixia Xu, Jimmy Zhu, Sinead Smith, et al.
Medrxiv : the Preprint Server for Health Sciences|September 15, 2025
Interim Analysis of Dose-Escalated Preoperative Breast Irradiation: A Phase Ib studyRavi Patel, Emilia Diego, Hayeon Kim, et al.
JCO Precision Oncology|November 14, 2025
Mixed Molecular Subtypes Coexist in Estrogen Receptor Heterogeneous Primary Breast CancersJulia Foldi, Kaitlyn Xiong, Matthew Liu, et al.
American Journal of Clinical Pathology|February 26, 2026
Magee Equation 3 demonstrates predictive and prognostic value for neoadjuvant chemotherapy outcomes in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancerJacob A Jerome, Rachel Vanderschelden, Beth Z Clark, et al.
Journal of the National Cancer Institute|August 14, 2025
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancerPaolo Tarantino, Do Lee, Julia Foldi, et al.
Pageof 5